Metro Healthcare BhdXKLS:0329 59 EBITDA Margin % is 23.90% as of Mar. 2026, which is 23% below its 10-year median of 30.95. GuruFocus rates XKLS:0329 with a GF Score™ of 59/100 and a GF Value™ of RM0.32 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Metro Healthcare Bhd ranks better than 90.06% on this metric.
Metro Healthcare Bhd (XKLS:0329) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Metro Healthcare Bhd EBITDA Margin % Related Terms
Metro Healthcare Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Metro Healthcare Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0329 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Metro Healthcare Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metro Healthcare Bhd EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Metro Healthcare Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Metro Healthcare Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metro Healthcare Bhd (XKLS:0329) has a EBITDA Margin % of 23.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metro Healthcare Bhd and its competitors. This is 23% below median its historical median of 30.95. Over the past decade, Metro Healthcare Bhd's EBITDA Margin % has ranged from 18.42 to 676.83. According to the industry distribution chart, Metro Healthcare Bhd ranks #66 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 9.9%.
Is Metro Healthcare Bhd's EBITDA Margin % too high?
Metro Healthcare Bhd's current EBITDA Margin % of 23.90% is 23% below median its 10-year median of 30.95. Over the past 10 years, this metric has ranged from a low of 18.42 to a high of 676.83. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Metro Healthcare Bhd's value of 23.90% is 134.1% above this industry median. Based on the distribution chart, Metro Healthcare Bhd ranks #66 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Metro Healthcare Bhd has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Metro Healthcare Bhd's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Metro Healthcare Bhd ranks #66 out of 664 companies for EBITDA Margin %. This places Metro Healthcare Bhd in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Metro Healthcare Bhd's value of 23.90% is 134.1% above this benchmark. Historically, Metro Healthcare Bhd's own EBITDA Margin % has ranged from 18.42 to 676.83 over the past decade. While the company's 10-year median is 30.95 vs. the industry median of 10.21, Metro Healthcare Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metro Healthcare Bhd's current EBITDA Margin % of 23.90% is 134.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metro Healthcare Bhd and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metro Healthcare Bhd's current EBITDA Margin % is 23.90%, which is 23% below median its own 10-year median of 30.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metro Healthcare Bhd stock overvalued right now?
Based on GuruFocus' analysis, Metro Healthcare Bhd (XKLS:0329) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.32, compared to a current price of RM0.22 — trading 32.8% below its estimated fair value. The current EBITDA Margin % is 23.90%, which is 23% below median its 10-year median of 30.95 and 134.1% above the Healthcare Providers & Services industry median of 10.21. Metro Healthcare Bhd's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Metro Healthcare Bhd (XKLS:0329), the current EBITDA Margin % is 23.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metro Healthcare Bhd (XKLS:0329) Overvalued in 2026?
Based on GuruFocus' analysis, Metro Healthcare Bhd stock appears to be undervalued.
The current stock price of RM0.22 is trading 32.8% below its estimated GF Value™ of RM0.32.
GuruFocus considers Metro Healthcare Bhd to be Possible Value Trap.
Key valuation signals for XKLS:0329:
EBITDA Margin %: 23.90% (23% below median its 10-year median of 30.95)
GF Value™: RM0.32 vs. price of RM0.22 (32.8% below fair value)
Industry Position: 134.1% above the Healthcare Providers & Services median (#66 of 664)
No single metric tells the full story. See the XKLS:0329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metro Healthcare Bhd is engaged in the provision of women healthcare services. The company offers various services such as obstetrics, gynecology impatient services, and diagnostic medical imaging services. It also provides semen analysis, intracytoplasmic sperm injection, blastocyst culture, assisted hatching, frozen embryo transfer, preimplantation genetic screening, and infertility consultation services. The company serves patients in Malaysia. The firm's business segment includes O&G healthcare services, Complementary services, and Hospital services.
59GF Score
Get the complete analysis for XKLS:0329
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0329 has been successfully added to your 
